This article reviews the concept and clinical manifestations of post embolism syndrome after transarterial chemoembolization(TACE),and the prevention or timely intervention of post embolism syndrome in advance is expe...This article reviews the concept and clinical manifestations of post embolism syndrome after transarterial chemoembolization(TACE),and the prevention or timely intervention of post embolism syndrome in advance is expected to reduce its incidence and degree in clinical treatment,and to improve the quality of treatment of Hepatocellular Carcinoma Carcinoma(HCC).展开更多
文摘目的探讨肝动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)与仑伐替尼及卡瑞丽珠靶向免疫治疗对不可切除肝癌患者短期疗效及T细胞亚群的影响。方法选取2021年5月—2023年10月厦门市中医院收治的76例不可切除肝癌患者为研究对象。以随机数字表法分为对照组(n=38)与研究组(n=38)。对照组采用TACE治疗,研究组采用TACE与仑伐替尼及卡瑞丽珠靶向免疫治疗。比较2组患者的短期疗效、T细胞亚群[簇分化抗原3(cluster of differentiation 3,CD3^(+))、簇分化抗原4(cluster of differentiation 4,CD4^(+))、簇分化抗原8(cluster of differentiation 8,CD8^(+))、CD4^(+)/CD8^(+)]、肝功能[丙氨酸氨基转移酶(alanine aminotrarsferase,ALT)、天门冬氨酸氨基转移酶(aspartate aminotransferase,AST)、总胆红素(total bilirubin,TBIL)]指标、肿瘤供血动脉直径和不良反应发生率。结果治疗后,研究组疾病控制率为89.47%,高于对照组的63.16%,差异有统计学意义(P<0.05)。研究组CD8^(+)为(20.30±1.78)%,低于对照组的(24.23±2.75)%;研究组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)分别为(73.25±6.48)%、(45.28±4.83)%、(2.23±0.24),高于对照组的(62.72±7.15)%、(37.54±4.32)%、(1.55±0.22),差异有统计学意义(P<0.001)。研究组ALT、AST、TBIL水平及肿瘤供血动脉直径分别为(42.35±8.48)U/L、(37.18±4.78)U/L、(16.88±2.58)μmol/L、(3.30±0.30)mm,低于对照组的(60.52±8.15)U/L、(53.53±5.75)U/L、(21.24±2.32)μmol/L、(3.80±0.30)mm,差异有统计学意义(P<0.001)。2组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论对不可切除肝癌患者采用TACE与仑伐替尼及卡瑞丽珠靶向免疫治疗具有比单纯TACE治疗更好的临床疗效,能改善T细胞亚群比例,提高患者免疫功能和肝功能,降低肿瘤供血动脉直径,抑制肿瘤迁移,改善病情。
文摘This article reviews the concept and clinical manifestations of post embolism syndrome after transarterial chemoembolization(TACE),and the prevention or timely intervention of post embolism syndrome in advance is expected to reduce its incidence and degree in clinical treatment,and to improve the quality of treatment of Hepatocellular Carcinoma Carcinoma(HCC).
